This is how HIV decides to become active
Researchers have found the molecular mechanism underpinning HIV’s decision to remain in an active or dormant state. This may lead to new therapies that work by keeping the virus in a permanently dormant state.
The study, led by a team from the Gladstone Institutes in San Francisco, CA, features in a paper now published in the journal Cell.
The findings may also explain cell fate decisions that occur elsewhere in biology — such as how stem cells decide whether to remain as stem cells or differentiate into specialized cells, including brain or heart cells, when they divide.
Senior study author Prof. Leor S. Weinberger, the director of the Center for Cell Circuitry at the Gladstone Institutes, likens the process to how we “hedge our bets” when we make decisions about financial investments.
To “protect against volatility in the market,” we may choose to place some funds in high-risk stocks with potentially high yields and the rest in low-risk, low-yield options.
“Similarly,” he explains, “HIV covers its bases in a volatile environment by generating both active and dormant infections.”
Once it enters the human body, HIV inserts its genetic material into the DNA of the “host” immune cells. Doing this enables HIV to force the cell’s machinery to make copies of the virus.
However, some HIV-infected immune cells go into a dormant, or latent, state and won’t make new virus. HIV can hide in this “latent reservoir” for a long time.
Current HIV treatments are highly effective at reducing the amount of active virus in the body. However, they are not so good at tackling dormant HIV, which can reactivate as soon as treatment stops. This is one of the main reasons that we cannot yet cure HIV.
In previous work, Prof. Weinberger and his colleagues showed that HIV latency “is not an accident” but a deliberate “survival tactic.”
The tactic is “evolutionarily advantageous for the virus” because in the sites where HIV first enters the body, there are not many immune cells for it to invade, and if it killed them all by being fully active, there would not be any left to carry on the infection.
By putting some of the cells that it invades into a latent state, HIV ensures that activation can wait until those cells have been carried into tissue where there are many more target cells, thereby ensuring a higher chance of survival and ongoing infection.
The team found that HIV is able to generate an active or a dormant state by taking advantage of a normal phenomenon inside cells that is called “random fluctuations in gene expression.”
Because of random fluctuations in gene expression, which scientists also call “noise,” two cells with exactly the same genetic makeup can produce different amounts of the same protein. The difference can be enough to influence cell “function and fate.”
HIV expresses its genes inside the host cell using a mechanism called “alternative splicing,” which enables it to slice up its genetic material and assemble it in a variety of arrangements.
In their study, the researchers observed individual cells infected with HIV. They found that the virus uses a type of splicing to control random noise to decide the fate of the host cell — whether to be active or dormant.
“We found,” says co-first study author Dr. Maike Hansen, a researcher in Prof. Weinberger’s group, “that HIV uses a particularly inefficient form of splicing to control noise.”
“Surprisingly, if it worked efficiently,” she continues, “this mechanism would produce much less active virus. But, by seemingly wasting energy through an inefficient process, HIV can actually better control its decision to remain active.”
With the help of modeling, genetics, and imaging tools, the team was able to identify, for the first time, the stage in the HIV life-cycle at which the splicing occurred.
They found that the inefficient splicing occurs not during transcription — as previously thought — but after it.
Transcription is the process through which instructions held in DNA are copied into RNA for telling cell machinery what to do or which proteins to make.
The team concludes that having an inefficient splicing process is vital for the survival of the virus, and that improving its efficiency could be a way to defeat it by keeping it permanently in a latent state.
About Taj Pharma
Taj Pharma India play a leading role in therapeutic areas such as cancer, virology and transplantation. The combined strengths of Taj Pharma generics and pharmaceuticals businesses, coupled with expertise in the emerging genetic sciences, equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients’ needs. Taj Pharmaceutical’s products and services address the entire healthcare spectrum, from screening for genetic risk factors, to preventing, diagnosing and treating disease, and monitoring the treatment response.